Genedrive PLC - Manchester, England-based molecular diagnostics company - Draws down £600,000 on its £5 million equity prepayment facility. In March last year, Genedrive agreed the £5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd. At the time it said that proceeds would be used towards the commercialisation of the antibiotic-induced hearing loss test, Genedrive MT-RNR1 ID Kit, and enhancing the Genedrive platform as well as providing additional working capital.

Current stock price: 8.20 pence

12-month change: down 33%

Copyright 2024 Alliance News Ltd. All Rights Reserved